Terns Pharmaceuticals
Taking the Journey Towards Comprehensive Treatment of Serious Disease
Foster City, United States
63 employees
Post Ipo Equity
Total: $348.30M
Biotechnology, Health Care +2
General Information
Get notified when Terns Pharmaceuticals moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track Terns Pharmaceuticals
Get real-time alerts for funding, hiring, news, and 40+ signal types.
Start Tracking — FreeDiscover More
United States Market
Biotechnology
Featured on Cnbc: Merck hikes revenue outlook as new drug sales grow, but cuts profit guidance due...
About Terns Pharmaceuticals
Taxonomy: biopharmaceutical, clinical-stage, oncology, obesity, small-molecule product candidates, allosteric BCR-ABL inhibitor, GLP-1 receptor agonist, THR-β agonist, GIPR modulator programs
Funding Rounds & Investors (5)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | •••••• | - | 20 Dec 2022 | |
| Post-IPO Equity | •••••• | 2 |
|
12 Aug 2022 |
| Series C | •••••• | 7 |
|
05 Jan 2021 |
| Series B | •••••• | 1 |
|
30 Oct 2018 |
| Series A | •••••• | - | 04 Apr 2018 |
Latest News
View All
Terns Pharmaceuticals Alternatives & Competitors
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development o...
Harnessing the power of microglia to transform treatments for neurodegenerative diseases
Precision-Guided Therapeutics
FAQ About Terns Pharmaceuticals
Don't just browse. Track.
Signal Tracker monitors Terns Pharmaceuticals and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.